Merck KGaA's Mavenclad stakes its claim in massively competitive MS market

Merck kgaa
Merck KGaA's Mavenclad hit €321 million ($358 million) in sales in 2019. (Merck KGaA)

In an increasingly crowded multiple sclerosis market, Merck KGaA's Mavenclad has scrapped for market share against behemoths such as Roche's Ocrevus. But a year into its U.S. launch, Mavenclad is posting exponential growth.

In 2019, Mavenclad raked in €321 million ($358 million) in global sales, a more than 250% increase from the €90 million it posted the previous year.

That significant leap has more than offset the sales loss from Merck KGaA's older MS med Rebif and represents a more than 5% share of the global MS market––up from 1% at the end of 2018, the drugmaker said. 

Merck KGaA tied Mavenclad's strong performance directly to its FDA approval in March, which made the drug the only oral short-term therapy for MS in the relapsing-remitting and active secondary progressive settings, the company said. 

RELATED: In crowded MS market, Merck KGaA's Mavenclad now offsets Rebif decline

Suggested Articles

Bayer has withdrawn part of a proposed Roundup settlement after a judge questioned how it's handling potential future claims.

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

The CEOs for COVID-19 vaccine partners Pfizer and BioNTech are sounding confident in their program as they gear up for phase 3.